10x Genomics announced a multi-year collaboration with Lausanne University Hospital to apply single-cell and spatial biology tools to biomarker discovery across advanced solid cancers. The program will use 10x platforms including Flex Apex and Xenium, with plans to expand to the company’s Atera system. Tumor samples will come from patients undergoing clinical molecular tumor board evaluation across indications including non-small cell lung cancer, breast cancer, bladder cancer, and melanoma. By integrating single-cell and spatial data with clinical outcome information, the partnership aims to identify clinically actionable biomarkers tied to treatment response and mechanisms of resistance. The collaboration underscores a growing push toward multimodal datasets that can translate into trial biomarker strategy and future diagnostic reporting. It also signals how major platform vendors are positioning their technologies directly for tumor-board workflows.